ReviewCurrent oncology (Toronto, Ont.)2025

Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options.

Jacob C Easaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.